Stevanato Group S.p.A.
DB:87N
Italy / Healthcare / Life Sciences Tools & Services
Exchange Data
Hide this widget
Price
18.50 EUR
Day change
0.00 (0.00%)
52-week range
15.50 - 29.40
Summary of Stevanato Group S.p.A.
Hide this widget
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare...
Price History
Chart Gallery
Hide this widget
1 Week
1 Month
3 Months
1 Year
5 Year
10 Years
- (-)
Data Explorer
Hide this widget
Data could not be retrieved
Peer Benchmarks
Hide this widget
Quote
Value
Size
Growth
Profit
| 87N | Peers | Sector | |
|---|---|---|---|
Market Cap | 5.151 B | 13.24 B | 57.946 M |
Price % of 52 Week High | Premium | 0.0% | 61.8% |
Dividend Yield | 0.3% | 0.0% | 0.0% |
Shareholder Yield | Premium | 2.1% | -0.7% |
1 Year Price Total Return | -36.9% | -22.6% | -13.2% |
Beta (5 Year) | 0.60 | 0.89 | 0.64 |
In the News
Hide this widget
No data available
Fair Value
Hide this widget
Average
–
Upside
–
Uncertainty
–
Spread
–
Financial Health
Health Details
Hide this widget
Financial Health for Stevanato is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.
12345
Financial Models for Stevanato Group S.p.A.
Model Gallery
Hide this widget
| DDM Multi StageView Updated 1 day ago |
| DDM Stable GrowthView Updated 1 day ago |
| DuPont ROE AnalysisView Updated 2 days ago |
| 10Y Historical FinancialsView Updated 2 days ago |
| 5Y Historical FinancialsView Updated 2 days ago |
| CAPM WACC ModelView Updated 1 day ago |
| Earnings Power ValueView Updated 1 day ago |
Historical Financials
Full Financials
Hide this widget
| (EUR in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 984 | 1,085 | 1,104 | 321 | 331 |
| Operating Income | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Net Profit | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Diluted EPS | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| EBITDA | |||||
| Balance Sheet | |||||
| Cash & ST Invest. | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Equity | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Debt | 219 | 397 | 430 | 397 | 430 |
| Cash Flow Statement | |||||
| Cash Flow Operations | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Investing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Financing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Free Cash Flow | (132) | (328) | (147) | (72) | (45) |
Analyst Notes
April 1, 2025
Hide this widget